RT Journal Article
T1 Hepatitis C Virus Clearance by Direct-Acting Antivirals Agents Improves Endothelial Dysfunction and Subclinical Atherosclerosis: HEPCAR Study.
A1 Muñoz-Hernández, Rocío
A1 Ampuero, Javier
A1 Millán, Raquel
A1 Gil-Gómez, Antonio
A1 Rojas, Ángela
A1 Macher, Hada C
A1 Gallego-Durán, Rocío
A1 Gato, Sheila
A1 Montero-Vallejo, Rocío
A1 Rico, María C
A1 Maya-Miles, Douglas
A1 Sánchez-Torrijos, Yolanda
A1 Soria, Isabel Carmona
A1 Stiefel, Pablo
A1 Romero-Gómez, Manuel
AB Hepatitis C virus (HCV) infection has been related to increased cardiovascular (CV) risk. The aim of this study was to analyze the impact of sustained virological response (SVR) on endothelial dysfunction and subclinical atherosclerosis in patients with hepatitis C virus treated with direct-acting antiviral agents. A total of 114 patients were prospectively recruited and underwent CV risk assessment including (i) endothelial dysfunction determined through laser Doppler flowmetry and (ii) subclinical atherosclerosis, elucidated by the ankle-brachial index (ABI). Atherogenic lipid profile (total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides); markers of oxidative stress (oxidized low-density lipoprotein antibodies [OLAbs]), soluble markers of adhesion (vascular cell adhesion molecule [VCAM], e-selectin, and soluble markers of angiogenesis; and vascular endothelial growth factor, endothelial [EMPs] and platelet [PMPs] apoptotic microparticles, and cell-free DNA [cfDNA]) were measured. All determinations were performed at baseline, 12 weeks (SVR time), and 1 year after treatment. In patients with endothelial dysfunction, area of hyperemia improved after virus clearance (P = 0.013) and was related to significant decrease in VCAM, e-selectin (P  HCV clearance improved not only liver function but also endothelial dysfunction and subclinical atherosclerosis promoted by decrease in levels of VCAM, e-selectin, cfDNA, and PMPs and EMPs.
YR 2020
FD 2020
LK https://hdl.handle.net/10668/27948
UL https://hdl.handle.net/10668/27948
LA en
DS RISalud
RD Apr 6, 2025